Company Summary

Kōli has developed a catheter-based solution for gallstone disease. Symptomatic gallstone disease affects more than 25 million people and consumes more than $20B globally. Surgical removal of the gallbladder is currently the only definitive treatment. Kōli offers a safer, non-surgical alternative which does not require general anesthesia or removal of the gallbladder. The device is currently undergoing clinical trials in Europe.

Team

Christopher Cheng

CEO

Chris has 20 years of experience in biomedical research and medical device development and is a Consulting Professor of Surgery at Stanford University. Chris graduated from Duke and Stanford, and was previously an Entrepreneur In Residence at NDC, General Manager of Tendyne Medical, Director of Technology of NovoStent, and Principal Engineer at J&J.

Matthew Callaghan

CMO

Matt is an alumnus of Stanford’s Biodesign Program and a Consulting Assistant Professor of Surgery at Stanford University. He graduated from Carnegie-Mellon and has an MD from the State University of NY. Matt trained in general surgery at UCSF and is the founder of three medical device companies including Kōli. Matt is a practicing physician at the San Francisco VA Medical Center.

Vrad has 15 years of experience in biomedical research and catheter-based medical device development. He graduated from U. Texas and Duke, and brought 7 devices to market as a medical device engineer at W.L. Gore & Associates.

Steven has over 20 years of experience in the medical device industry, with experience ranging from early R&D exploration to commercialization. He has worked for Haemonetics, Cordis, Intella Interventional, Abbott Labs, iScience Interventional, and Transcend Medical.